Skye Bioscience to host KOL event ahead of obesity drug trial results

SAN DIEGO - Skye Bioscience, Inc. (NASDAQ:SKYE), which maintains a "GREAT" financial health score according to InvestingPro analysis, will host a virtual expert panel on September 4 to discuss the upcoming topline results from its Phase 2a CBeyond trial of nimacimab, the company’s peripheral CB1 antibody being developed for obesity treatment. The company’s stock has shown notable momentum, delivering a 19.5% return over the past year despite characteristic biotech sector volatility.

The event, titled "Expert Panel on Peripheral CB1 Inhibition as a Mechanism for Weight Loss," will feature obesity specialists who will address what constitutes success in the proof-of-concept study and discuss the potential role of peripheral CB1 inhibition as a therapeutic pathway for obesity.

According to a company press release, the panel will include Dr. Kevin Cannon, who has served as principal investigator on more than 50 metabolic studies; Dr. Sean Wharton, lead author of the 2020 Canadian Obesity Guidelines; and Dr. Marcus Goncalves, Director of Systemic Metabolism Research at NYU Langone Health. The company’s strong balance sheet position, with cash reserves exceeding debt levels, provides financial flexibility for its ongoing clinical development programs.

Punit Dhillon, Skye’s Chief Executive Officer, stated the event aims to provide clarity ahead of the trial’s data readout, though the company will not be previewing clinical results.

The discussion will focus on safety and tolerability considerations, particularly gastrointestinal outcomes and neuropsychiatric factors relevant to the CB1 class of drugs. The company also plans to share new preclinical data during the event.

Nimacimab is described as a first-in-class peripheral CB1 antibody. The ongoing Phase 2a trial is also assessing the combination of nimacimab with the GLP-1 receptor agonist Wegovy.

Registration for the webcast is required to participate, and a replay will be available on the company’s website following the event. For investors interested in deeper analysis of biotech companies like Skye Bioscience, InvestingPro offers comprehensive research reports covering financial health metrics, valuation analysis, and expert insights across more than 1,400 US-listed companies.

In other recent news, Skye Bioscience reported its Q2 2025 earnings, which revealed a notable rise in research and development expenses. This increase contributed to a net loss of $17.6 million for the quarter. The company attributed the loss to strategic investments in its obesity treatment pipeline. Despite these developments, the earnings report has raised some concerns among investors about the company’s long-term profitability. Additionally, the financial results did not include any mergers or acquisitions during this period. Analysts have not indicated any upgrades or downgrades for Skye Bioscience following this report. The focus remains on how the company will manage its R&D expenses moving forward. These recent developments highlight the ongoing challenges and strategic priorities for Skye Bioscience.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.